

DAFTAR PUSTAKA

- Andreas, B. and Clotilde, B. (2020) 'The CC and CXC Chemokines : Major Regulators of Tumor Progression and the Tumor Microenvironment' , pp. 542–551. doi: 10.1152/ajpcell.00378.
- Beverly, A. T. and Simon, P. F. (2010) 'CXCL12 (SDF-1) / CXCR4 Pathway in Cancer' , pp. 2927–2931. doi: 10.1158/1078-0432.CCR-09-2329.
- Bindley, B. et al. (2015) 'Breast Cancer Metastasis and The Lymphatic System (Review)' , pp. 1233–1239. doi: 10.3892/ol.2015.3486.
- Blackburn, H. L. et al. (2017) 'Breast cancer metastasis to the axillary lymph nodes: Are changes to the lymph node "Soil" localized or systemic?', *Breast Cancer: Basic and Clinical Research*, pp. 1–5. doi: 10.1177/1178223417691246.
- Cabioglu, N. et al. (2005) 'Chemokine Receptors in Advanced Breast Cancer : Differential Expression in Metastatic Disease Sites with Diagnostic and Therapeutic Implications', pp.1013–1019. doi: 10.1093/annonc/mdn740.
- Christiansen, A. and Detmar, M. (2011) 'Lymphangiogenesis and Cancer' , pp. 1146–1158. doi: 10.1177/1947601911423028.
- Claudia, T. et al. (2019) 'CXCR4 Signalling, Metastasis and Immunotherapy : Zebrafish Xenograft Model as Translational Tool for Anti-Cancer Discovery' , pp. 1–11. doi: 10.20517/2394-4722.2019.022.
- Collins, L. C. (2018) 'Breast', in Goldblum, J. R. et al. (eds) *Rosai and Ackerman's Surgical Pathology*. 11th edn. Philadelphia: Elsevier, pp. 1434–1529.
- Debarati, D. and Jihe, Z. (2013) 'The Role of Chemokine Receptors CXCR4 in Breast Cancer Metastasis' , *Review Article*, pp. 46–57.
- Donald, W. and Walter, K. (2008) 'Translating an Antagonist of Chemokine Receptor CXCR4 : From Bench to Bedside' , pp. 7975–7980. doi: 10.1158/1078-0432.CCR-07-4846.
- Edneia, A. S. R. et al (2011) 'Epigenetic Changes of CXCR4 and Its Ligand CXCL12 as Prognostic Factors for Sporadic Breast Cancer' , pp. 1–10. Available at: www.plogsone.org.
- Ellenson, L. H. and Lester, S. C. (2018) 'Female Genital System and Breast', in Kumar, V., Abbas, A. K., and Aster, J. C. (eds) *Robbins Basic Pathology*. 10th edn. Philadelphia: Elsevier, pp. 736–747.
- Erwin, D. Y. et al. (2021) 'CXCR4 and RANK Combination as a Predictor of Breast Cancer Bone Metastasis in Indonesia' , *Research Article*, pp. 20–24. doi: 10.17352/2455-2968.000130.
- Fabrice, A. et al. (2009) 'CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence' , pp. 1182–1189. Available at: www.TheOncologist.com.

- Florinda, I. and Endah, Z. (2019) 'Peran dan Fungsi CXCR4 (CXCR-4) pada Keganasan'. *Pratista Patologi* Vol. 6, pp. 1–5.
- George, S. W. (2013) 'The Chemokine System, and Its CCR5 and CXCR4 Receptors, as Potential Targets for Personalized Therapy in Cancer' , pp. 1–18. doi: 10.1016/j.canlet.2013.10.006.
- Ghalib, A. (2009) 'The Biology of CCR5 and CXCR4' , pp. 1–6. doi: 10.1097/COH.0b013e328324bbec.
- Globocan. (2020) 'Breast Cancer – The Global Cancer Observatory'.
- Hua Kang. Et al. (2005) 'The Elevated Level of CXCR4 is Correlated with Nodal Metastasis of Human Breast Cancer' , pp. 360-366. doi: 10.1016/j.breast.2004.12.007.
- Jan, A. B and Thomas, J. K. (2006) 'CXCR4 : A Key Receptor in the Crosstalk Between Tumor Cell and Their Microenvironment' , pp. 1761–1766. doi: 10.1182/blood-2005-08-3182.
- Jonk, O. K. et al. (2009) 'Expression of CXCR4 and SDF-1 α in Breast Cancers and Metastatic Lymph Nodes' , pp. 249–256. doi: 10.4048/jbc.2009.12.4.249.
- Karolina, A. Z. and Vladimir, L. K. (2020) 'The Signaling Duo CXCL12 and CXCR4 : Chemokine Fuel for Breast Cancer Tumorigenesis' , pp. 1–21. doi: 10.3390/cancer12103071.
- Kumar, Abbas, Aster. et al. (2018) 'The Breast' , in Susan, C.L. (eds). *Robbin and Cotran Pathologic Basis of Disease*. 9th edn. Philadelphia: Elsevier, pp.1051–1056.
- Kryczek, I. et al. (2007) 'Stroma-Derived Factor (SDF-1/CXCL12) and Human Tumor Pathogenesis' , pp. 987–994. doi: 10.1152/ajpcell.00406.
- Liu. et al. (2020) 'Chemokines and Chemokine receptors : A New Strategy For Breast Cancer Therapy (Review)' , pp. 3786–3796. doi: 10.1002/cam4.3014.
- Marina, O. K. et al. (2015) 'Immunohistochemical Expression of CXCR4 on Breast Cancer and Its Clinical Significance' , pp. 1–5. doi: 10.1155/891020.
- Nathanson, S. D. (2003) 'Insights into the mechanisms of lymph node metastasis', *Cancer*, 98(2), pp. 413–423. doi: 10.1002/cncr.11464.
- Polina, W. and Adit, B. (2013) 'The Chemokine System, and its CCR5 and CXCR4 Receptors, as Potensial Targets for Personalized Therapy in Cancer' , pp. 1 –18. doi: org/10.1016/j.canlet.2013.10.006.
- Rakha, E., Allison, K., Bu, H., et al. (2019) 'Invasive Breast Carcinoma of No Special Type', in Lokuhetty, D. et al. (eds) *WHO Classification of Tumours Breast Tumours*. 5th edn. France: International Agency for Pesearch on Cancer (IABC), pp. 102–109.
- Rakha, E., Allison, K., Ellis, I. et al. (2019) 'Invasive Breast Carcinoma: General Overview', in Lokuhetty, D. et al. (eds) *WHO Classification of*

- Tumours Breast Tumours*. 5th edn. France: International Agency for Research on Cancer (IARC), pp. 82–101.
- Rahman, M. and Mohammed, S. (2015) 'Breast cancer metastasis and the lymphatic system (Review)', *Oncology Letters*, 10(3), pp. 1233–1239. doi: 10.3892/ol.2015.3486.
- Ran, S. et al. (2011) 'NIH Public Access', 17(4), pp. 229–251. doi: 10.1016/j.pathophys.2009.11.003.Lymphangiogenesis.
- Ran, S. et al. (2009) 'Lymphangiogenesis and Lymphatic Metastasis in Breast Cancer', pp. 229–251. doi: 10.1016/j.pathophys.2009.11.003.
- Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, et al. (2006) 'The Role of CXCR4 Receptor Expression in Breast Cancer: A Large Tissue Microarray Study. *Breast Cancer Research and Treatment*', pp. 275–283.
- Shen, S. et al. (2015) 'Correlation of lymphovascular invasion with clinicopathological factors in invasive breast cancer: a meta-analysis', pp. 17789–17795.
- Speetjens, F. M, Liefers, G. J, Korbee CJ, Mesker WE, van de Velde CJH, et al. (2009) 'Nuclear Localization of CXCR4 Determines Prognosis for Colorectal Cancer Patients. *Cancer Microenvironment*', pp. 1-7
- Stefania. S. (2015) 'Molecular Pathway : Targeting the CXCR4-CXCL12 Axis – Untapped Potential in the Tumor Microenvironment', pp. 4278–4283. doi: 10.1158/1078-0432.ccr1409114.
- Su, Y. C. et al (2005) 'Expression of CXCR4 is Associated with Axillary Lymph Node Status in Patients with Early Breast Cancer', pp. 533–539. doi: 10.1016/j.breast.2005.08.034.
- Toss, A. et al. (2017) 'Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?', *International Journal of Molecular Sciences*, 18(85), pp. 1–24. doi: 10.3390/ijms18010085.
- Trianto, H. F, et al. (2019) 'Korelasi Antara Status Metastatik Kelenjar Getah Bening Aksila Dengan Ekspresi CD44 dan CXCR4 pada Karsinoma Payudara', *Majalah Kesehatan*. Volume 6, pp. 134–145.
- Urszula, M. D, et al. (2012) 'A Review on CXCR4/CXCL12 Axis in Oncology: No Place to Hide', pp. 219–230. doi.org/10.1016/j.ejca
- Wang L, Wang Z, Yang B, Yang Q, et al. (2009) 'CXCR4 Nuclear Localization Follows Bindings of its Ligand SDF-1 and Occurs in Metastatic but Not Primary Renal Cell Carcinoma', *Oncology Reports*, pp. 1333-1339.
- Wayan, S. and Wayan, P. S. Y. (2013) 'C-X-C Receptor 4 (CXCR4) Metastasis Kanker Payudara', pp. 126–131. doi: 10.24293/ijcpml.v19i2.1068.

- Xu, C. et al. (2015) 'CXCR4 in Breast Cancer : Oncogenic Role and Therapeutic Targeting (Review)' , pp. 4953–4964. doi: 10.2147/DDDT.S84932.
- Yanan, S., Xiaoyun, M. et al. (2014) 'CXCL12-CXCR4 Axis Promotes The Natural Selection of Breast Cancer Cell Metastasis' , *Research Article*, pp. 7765–7773. doi: 10.1007/s13277-014-1816-1.
- Yasuoka H, Tsujimoto M. et al. (2008) 'Cytoplasmic CXCR4 Expression in Breast Cancer: Induction by Nitric Oxide and Correlation with Lymph Node Metastasis and Poor Prognosis' , pp. 1–10.
- Zhang. et al. (2014) 'Expression of CXCR4 and Breast Cancer Prognosis : a Systematic Review and Meta-Analysis' , *Research Article*, pp. 1–8. Available at: www.biomedcentral.com.

LAMPIRAN

Lampiran 1: Tabulasi Data

No Urut	No Sediaan	Usia	Grade	LVI	Metastasis	Intensitas (IS)	Proporsi (PR)	IR = ISxPR	Status Ekspresi
1	35116	51	1	2	1	3	3	9	1
2	38121	64	1	1	1	2	3	6	1
3	45046	45	1	2	1	3	3	9	1
4	39801	56	1	2	1	1	2	2	2
5	42844	34	1	1	1	3	3	9	1
6	34243	52	1	1	1	2	3	6	1
7	38398	44	1	1	1	3	2	6	1
8	46800	48	1	1	1	3	3	9	1
9	40820	35	1	1	1	3	3	9	1
10	H19. 1279	52	1	1	1	2	3	6	1
11	H19. 149	58	1	1	1	2	3	6	1
12	H19. 1280	49	1	1	1	3	2	6	1
13	H19. 1164	46	1	1	1	3	4	12	1
14	H19. 1329	49	1	1	1	3	3	9	1
15	H19. 1075	45	1	1	1	3	3	9	1
16	H19. 1360	61	1	1	1	2	4	8	1
17	H19. 998	54	1	1	1	2	3	6	1
18	H20. 778	49	1	1	1	3	3	9	1
19	H19.698	38	2	1	1	3	4	12	1
20	H19. 637	37	2	1	1	3	3	9	1
21	H19. 1134	46	2	1	1	3	3	9	1
22	H19. 969	57	2	1	1	3	4	12	1
23	H19. 1035	70	2	1	1	3	4	12	1
24	H19. 357	78	2	1	1	2	3	6	1
25	H19. 377	63	2	1	1	3	4	12	1
26	H19. 331	68	2	1	1	3	3	9	1
27	H19. 323	53	2	1	1	3	3	9	1
28	H20. 493	47	2	1	1	3	4	12	1
29	H20. 456	55	2	1	1	3	4	12	1
30	H20. 803	45	2	1	1	3	3	9	1
31	37369	36	2	1	1	2	2	4	1
32	45977	58	2	2	1	2	3	6	1
33	41721	48	2	2	1	3	3	9	1
34	38643	54	2	1	1	2	2	4	1
35	39618	72	2	1	1	2	3	6	1
36	38941	42	2	1	1	3	3	9	1
37	39677	51	2	2	1	1	2	2	2
38	48217	49	2	2	1	3	4	12	1
39	38166	50	2	1	1	3	4	12	1
40	38942	43	2	1	1	3	3	9	1
41	38603	61	2	1	1	3	4	12	1
42	38166	50	2	1	1	3	4	12	1

No Urut	No Sediaan	Usia	Grade	LVI	Metastasis	Intensitas (IS)	Proporsi (PR)	IR = ISxPR	Status Ekspresi
43	37369	63	2	1	1	3	3	9	1
44	35215	60	3	1	1	3	4	12	1
45	38922	42	3	2	1	3	3	9	1
46	34053	44	3	2	1	3	3	9	1
47	37530	56	3	1	1	2	2	4	1
48	45994	50	3	2	1	3	4	12	1
49	42383	54	3	1	1	2	3	6	1
50	40091	49	3	1	1	1	2	2	2
51	38603	61	3	1	1	3	4	12	1
52	32328	43	3	1	1	1	3	3	2
53	33999	67	3	1	1	3	3	9	1
54	33366	65	3	1	1	3	3	9	1
55	32015	34	3	2	1	3	3	9	1
56	38536	42	3	1	1	3	3	9	1
57	32683	40	3	1	1	2	2	4	1
58	33008	50	3	1	1	2	3	6	1
59	32562	62	3	1	1	2	2	4	1
60	38462	78	3	1	1	3	3	9	1
61	43732	41	3	1	1	3	4	12	1
62	48983	42	3	1	1	2	2	4	1
63	45994	50	3	2	1	3	3	9	1
64	49009	61	3	1	1	3	3	9	1
65	37710	50	3	1	1	3	3	9	1
66	H19. 1307	42	3	1	1	3	3	9	1
67	H19. 927	61	3	1	1	3	3	9	1
68	H19. 062	32	3	2	1	1	2	2	2
69	H19. 372	60	3	1	1	3	4	12	1
70	H20. 686	42	3	1	1	3	3	9	1
71	H20. 448	70	3	1	1	3	3	9	1
72	H20. 477	36	3	1	1	3	4	12	1
73	H19. 998	54	1	2	2	1	3	3	2
74	H19. 501	58	1	2	2	2	1	2	2
75	H19. 1085	52	1	2	2	3	1	3	2
76	38638	39	1	2	2	2	1	2	2
77	34316	43	1	2	2	3	1	3	2
78	31488	47	1	2	2	2	1	2	2
79	42330	33	1	2	2	2	1	2	2
80	H19. 762	83	2	2	2	2	1	2	2
81	H19. 827	43	2	2	2	2	1	2	2
82	H19. 026	56	2	2	2	2	3	6	1
83	H19. 862	50	2	2	2	2	3	6	1
84	H19. 1451	58	2	1	2	3	3	9	1
85	H19. 875	43	2	1	2	3	3	9	1
86	H19. 1042	56	2	1	2	3	2	6	1
87	H19. 864	56	2	2	2	2	1	2	2

No Urut	No Sediaan	Usia	Grade	LVI	Metastasis	Intensitas (IS)	Proporsi (PR)	IR = ISxPR	Status Ekspresi
88	H20. 612	58	2	2	2	2	3	6	1
89	H20. 447	88	2	1	2	3	3	9	1
90	H20. 634	48	2	2	2	2	3	6	1
91	40522	33	2	2	2	2	1	2	2
92	39599	43	2	2	2	2	1	2	2
93	41954	58	2	2	2	2	1	2	2
94	39677	51	2	2	2	2	1	2	2
95	H19. 1458	59	3	1	2	3	2	6	1
96	H19. 047	45	3	1	2	2	3	6	1
97	40827	59	3	2	2	2	1	2	2
98	31511	44	3	2	2	2	1	2	2
99	44316	53	3	2	2	2	1	2	2
100	40218	49	3	2	2	2	1	2	2

Lampiran 2: Persetujuan Etik


KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
 Contact Person: dr. Agussalim Bukhari, MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431



REKOMENDASI PERSETUJUAN ETIK

Nomor : 619/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 27 September 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21090580		No Sponsor	
Peneliti Utama	dr. Lidya Mamonto		Sponsor	
Judul Peneliti	Hubungan Ekspresi CXC Chemokine Reseptor 4 (CXCR4) Dengan Derajat Histopatologi Dan Kejadian Metastasis Ke Kelenjar Getah Bening Pada Karsinoma Payudara Invasif			
No Versi Protokol	1	Tanggal Versi	21 September 2021	
No Versi PSP		Tanggal Versi		
Tempat Penelitian	RS Universitas Hasanuddin Makassar			
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku	27 September 2021 sampai 27 September 2022	
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan		
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan		

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Lapo SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan